All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms?

Featured:

Michael OzgaMichael OzgaCaner SayginCaner SayginAbhay SinghAbhay Singh

Jun 9, 2020


During the American Society of Clinical Oncology (ASCO) Annual Meeting, Alexander Maurer from the AML Hub hosted a group discussion with Michael Ozga and Caner Saygin, both from The Ohio State University, Columbus, US and Abhay Singh from Roswell Park Comprehensive Cancer Center, Buffalo, US. This podcast discusses how the type of prior treatment can affect the risk of therapy-related myeloid neoplasms.

How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms?

The group start by discussing the problems clinicians face when deciding treatment plans for patients with secondary myeloid neoplasms and describe how exposure to prior DNA damaging agents, cytotoxic therapies, and genotoxic therapies, can lead to a complex karyotype in these patients.

The group then discuss the role of clonal hematopoiesis in the evolution of secondary myeloid neoplasms. Dr Saygin describes how this could be a possibility especially for TP53 mutated, therapy-related AML, he also provides another hypothesis that genotoxic agents could cause de novo mutations. The group also discuss other driving mutations for clonal hematopoiesis including MPN1, SRSF2, and ASXL1, before moving on to discuss how specific genotoxic therapies can generate specific mutations. Dr Saygin and Dr Ozga describe their study in which they analyzed the molecular footprint of patients who had received various genotoxic and cytotoxic agents in order to answer this. Dr Singh also discusses his data on how the development of novel agents, such as immunotherapies may actually reduce the risk of secondary myeloid neoplasms compared to previous treatment options.

The discussion ends on the note that these types of studies will eventuality allow clinicians to predict disease risk better and provide more suitable therapies based on the patient's particular molecular profile.


Your opinion matters

What barriers do you encounter when conducting multiple MRD tests during treatment?